---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-006227"
form_type: "8-K"
ticker: "ERNA"
cik: "0000748592"
company_name: "Ernexa Therapeutics Inc."
filed_at: "2026-02-11T23:59:59+00:00"
generated_at: "2026-05-16T03:27:03.792769+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Ernexa Therapeutics prices $10.5M public offering of 21M shares and warrants

## Summary
- Offering of 21M shares of common stock (or equivalents) and warrants to buy 21M shares at $0.50 per unit.
- Gross proceeds expected ~$10.5M; net proceeds for development programs, working capital, and general purposes.
- Warrants exercisable at $0.68/share, expire 5 years from issuance or 180 days after release of Phase 1 ERNA-101 data.
- Brookline Capital Markets acted as exclusive placement agent; offering closed Feb 10, 2026.
- Potential additional $14.3M if all warrants exercised on cash basis (no assurance given).

## SEC filing metadata
- accession: 0001493152-26-006227
- form_type: 8-K
- ticker: ERNA
- cik: 0000748592
- company_name: Ernexa Therapeutics Inc.
- filed_at: 2026-02-11T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/748592/000149315226006227/0001493152-26-006227-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/748592/000149315226006227/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-006227
- JSON: https://secwatch.observer/filing/0001493152-26-006227.json
- Plain text: https://secwatch.observer/filing/0001493152-26-006227.txt

## Source-grounded claims
- claim_id: 0b72ad23552c231a8c3f5d27eb72039ebb6aa135
  claim: Ernexa Therapeutics Inc. entered into Warrant Agent Agreement with Computershare Inc. and Computershare Trust Company, N.A. (effective 2026-02-10).
  evidence_excerpt: On February 10, 2026, the Company also entered into a Warrant Agent Agreement (the “Warrant Agent Agreement”) with Computershare Inc. and Computershare Trust Company, N.A. (collectively, “Computershare”),
  evidence_url: https://www.sec.gov/Archives/edgar/data/748592/000149315226006227/0001493152-26-006227-index.htm
- claim_id: 280a006f51427f05de817e9e05dc0d3e55098296
  claim: Ernexa Therapeutics Inc. entered into Purchase Agreement with certain investors (effective 2026-02-06).
  evidence_excerpt: In connection with the Offering, the Company also entered into a securities purchase agreement (each, a “Purchase Agreement”) with certain investors who purchased Shares, Pre-Funded Warrants and Warrants in the Offering.
  evidence_url: https://www.sec.gov/Archives/edgar/data/748592/000149315226006227/0001493152-26-006227-index.htm
- claim_id: f0d9b5ce23bc632ab531d95493fe26df5a9e5fd5
  claim: Ernexa Therapeutics Inc. entered into Placement Agency Agreement with Brookline Capital Markets, a division of Arcadia Securities, LLC (effective 2026-02-06).
  evidence_excerpt: On February 6, 2026, Ernexa Therapeutics Inc., a Delaware corporation (the “Company”), entered into a placement agency agreement (the “Placement Agency Agreement”) with Brookline Capital Markets, a division of Arcadia Securities, LLC
  evidence_url: https://www.sec.gov/Archives/edgar/data/748592/000149315226006227/0001493152-26-006227-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.